
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial visibility until Q1 2027 Three strategic agreements signed …